CIK 0001595097
- Non-accelerated filer
- Smaller reporting company
Corbus Pharmaceuticals Holdings, Inc.
Sign in to watch- Ticker
- CRBP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464348039
- Phone
- +1 617-963-0103
- Business address
- 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062
- Former names
- SAV Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,758,438
- in 2 filings, $16K under 10b5-1 plans
Net −$1,758,438. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 12 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-07 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −17,000 | $10.08 | $171K | 157,316 |
| 2026-02-13 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −13,871 | $7.78 | $108K | 174,316 |
| 2026-01-14 | Cohen Yuval Chief Executive Officer | Grant or award | +50,000 | 188,187 | ||
| 2026-01-14 | Cohen Yuval Chief Executive Officer | Grant or award · Stock options (right to buy) | +150,000 | 150,000 | ||
| 2025-10-27 | Cohen Yuval Chief Executive Officer | Exercise or conversion 10b5-1 | +8,973 | $4.26 | $38K | 147,160 |
| 2025-10-27 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −8,973 | $17.14 | $154K | 138,187 |
| 2025-10-27 | Cohen Yuval Chief Executive Officer | Exercise or conversion · Stock options (right to buy) 10b5-1 | −8,973 | 22,106 | ||
| 2025-10-24 | Cohen Yuval Chief Executive Officer | Exercise or conversion 10b5-1 | +18,660 | $4.26 | $79K | 156,847 |
| 2025-10-24 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −18,660 | $17.01 | $317K | 138,187 |
| 2025-10-24 | Cohen Yuval Chief Executive Officer | Exercise or conversion · Stock options (right to buy) 10b5-1 | −18,660 | 31,079 | ||
| 2025-02-14 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −7,134 | $8.76 | $62K | 138,187 |
| 2025-01-31 | Cohen Yuval Chief Executive Officer | Grant or award | +68,100 | 145,321 | ||
| 2025-01-31 | Cohen Yuval Chief Executive Officer | Grant or award · Stock options (right to buy) | +228,800 | 228,800 | ||
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Exercise or conversion 10b5-1 | +11,667 | $30.00 | $350K | 96,067 |
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −11,667 | $42.24 | $493K | 84,400 |
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Exercise or conversion 10b5-1 | +1,770 | $14.10 | $25K | 86,170 |
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −1,770 | $42.24 | $75K | 84,400 |
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Exercise or conversion 10b5-1 | +2,322 | $4.26 | $10K | 86,722 |
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −2,322 | $42.24 | $98K | 84,400 |
| 2024-06-18 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −7,179 | $42.24 | $303K | 77,221 |
Page 1 of 4 · 79 trades